Clinical Trial Update: sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for sEphB4-HSA in metastatic castration-resistant prostate cancer; status not clearly specified and results posted date provided, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Carcinoma
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• sEphB4-HSA

Snippet

Sponsor: Northwestern University | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: UNKNOWN | Results posted: 2022-04-27